Feasibility Study of BMAC Enhanced CABG
Feasibility Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting(CABG) Surgery
Sponsor: Harvest Technologies
Terminated
Pilot results in change to protocol, new study needed.
Other terminated trials from Harvest Technologies
- Cervical Myelopathy · Phase NA · Apr 2017
- Congestive Heart Failure · Phase PHASE1/PHASE2 · Dec 2013
- Diabetes · Phase NA · Sep 2005
More terminations from Harvest Technologies
Other Congestive Heart Failure trials with similar outcome
This PHASE1/PHASE2 trial investigates Congestive Heart Failure and is currently terminated or withdrawn. Harvest Technologies leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Harvest Technologies
- University of Utah
For direct contact, visit the study record on ClinicalTrials.gov .